Scythian Biosciences Corp. (TSX.V: SCYB) is a pre-clinical research and development company that is in the process of developing drug therapies. The first project underway is the development of a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. In addition to this primary line of research and development, Scythian also intends to develop other potential cannabinoid and non-cannabinoid based pharmaceutical products, including one that is in development for treatment of gastro-inflammatory disease.
Scythian Biosciences Corp.
366 Bay St. Suite 200
Toronto, ON, M5H 4B2
Scythian Biosciences Inc. is a pre-clinical research and development company that is in the process of developing drug therapies. The first project underway is the development of a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. In addition to this primary line of research and development, Scythian also intends to develop other potential cannabinoid and non-cannabinoid based pharmaceutical products, including one that is in development for treatment of gastro-inflammatory disease.
Introducing Scythian Biosciences: Developing Novel Concussion Therapy
Scythian Biosciences: Pre-Clinical Trials Underway for Novel Concussion Therapy
Could a Pill Treat Concussions? - Gillian Hotz, Ph.D.
The partnership between the University of Miami and the Canada-based Scythian Biosciences aims to propel this research and potential treatment forward by using two classes of drugs in a combination that scientists believe will reduce brain inflammation and the immune response.
Could a Pill Treat Concussions? - Michael Hoffer, M.D.
Introducing Scythian Biosciences Developing Novel Concussion Therapy
Scythian Biosciences (TSX.V: $SCYB.V) Talks about #Cannabinoid Treatment for TBI
CEO, Chairman and Director
Mr. Gilbert's professional experience spans two decades of corporate finance and technology start-up development. In addition to his position as Chief Executive Officer and director of Scythian Biosciences Inc., Mr. Gilbert is business development manager at Decision Nutrition, a multimedia nutrition consultancy company founded by his wife, Keren Gilbert. Prior to founding Scythian Biosciences Inc., served as President of New York-based Gilbert Capital Management Corp. for 14 years. Mr. Gilbert received his Bachelor of Business Administration from The George Washington University (BBA) and a Masters of Business Administration from Kennedy Western University (MBA). Mr. Gilbert lives in Roslyn Heights, NY, with his wife and their three sons.
Chief Financial Officer
Mr. Held is a chartered professional accountant, chartered accountant, with CFO level experience with both private and public companies. Mr. Held has worked with a number of start-up companies in a number of sectors including technology, real estate and resources, both domestic and international. Mr. Held has been involved in numerous successful public market transactions including Initial Public Offerings, Reverse Takeovers and financing. Mr. Held holds a Bachelor of Mathematics and Masters of Accounting from the University of Waterloo.
Chief Operating Officer
Mr. Schrader has been a practicing business lawyer and consultant for over 29 years and is the developer and inventor of the Company's drug therapy. David is currently a partner at the law firm of Moritt Hock & Hamroff. In addition to his private legal practice, David has previously been general counsel and principal for Laconia Capital, a FINRA licensed broker dealer; general counsel and V.P. of strategic management of K-Tex, LLC, a Chinese trading company. David holds numerous educational credentials, including an LLM in Business Transactions from the University of Alabama School of Law; a Masters in Global Management from the Thunderbird School of Global Management; both an MBA and Masters in Strategic Management from the Kelley School of Business, Indiana University; a J.D. degree from the Benjamin N. Cardozo School of Law; and a Bachelors in Biology, emphasizing in cell and molecular biology and biochemistry, from Johns Hopkins University. David's credentials also include certification programs in Supply Chain Management (Kelley School of Business); Chief Sustainability Officer Training (SSC); Management Practices (Freeman School of Business, Tulane University); and Bioethics (Albert Einstein School of Medicine)
Chief Scientific Officer
Mr. Dariani has over 35 years of diverse and progressive management experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani has a successful record of business management, strategic planning, acquisition and divestiture, project management, production management, R&D management, economic evaluations, competitor analyses, and development and administration of multi-million dollar budgets. Mr. Dariani is an entrepreneurial business leader with a sound grasp of successful business strategies, an excellent foundation in science and engineering, and a strong background in product development and commercialization. He is currently the CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer. Mr. Dariani also leads Myos Rens' science and technology efforts and has overall responsibilities for manufacturing, basic science, pre-clinical and clinical studies. Prior to joining Semorex Inc., Mr. Dariani was President of Focus Pharmaceuticals, Inc ("Focus") where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage. Prior to joining Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation ("Celgene"). During his twelve years at Celgene, Mr. Dariani developed and implemented Celgene's manufacturing strategy, managed and successfully sold Celgene's chiral intermediates business unit, and formulated a strategic plan for leveraging Celgene's expertise in chiral technologies towards the development of chirally pure drug products. Mr. Dariani was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names. Prior to Celgene, Mr. Dariani held progressively more responsible engineering and development positions at Celanese Corporation. Mr. Dariani holds a Bachelor of Science from The City College of New York and a Master of Science from University of Massachusetts in Chemical Engineering. Mr. Dariani is a member of Board of Directors at Semorex Inc. and Mesa Therapeutics.
Gary Leong is the Chief Scientific Officer of Aphria Inc., a Health Canada Licensed Producer of medical cannabis products. Gary has a personal background in quality assurance, quality control, quality system audits, international and domestic regulatory affairs and product research and development. Gary currently is the president of Neautrical Solutions Inc. located in Surrey, British Columbia. Prior to that, he was the Chief Scientific Officer at Jamieson Laboratories Limited. He began at Jamieson in the year 2000 as the Vice President of Scientific and Technical Affairs. He also held the position of Quality Control Manager at Boehringer Ingelheim Consumer Products: Quest Vitamins and Development Officer at Atomic Energy of Canada: Radiochemical Company. Gary's educational background began with a Bachelors of Science in Chemistry and has taken him most recently to an MBA in Quality Management from City University of Bellevue Washington. Gary is currently affiliated with The Life Sciences Working Team of Windsor-Essex Economic Development Corporation. In the past, he was a member of the Natural Health Products Directorate Program Advisory Committee and a board member of the Ontario Ginseng Innovation and Research Consortium.
Mr. Petter is the CEO of Mikrofax eProcurement Solutions, an international San Francisco based software development company that specializes in SaaS based supply chain management workflow tools. A native of London England, Michael has a personal background in software development and strategic management with special focus on product marketing and customer satisfaction. Michael is recognized as a leader in the field of automated supply chain management solutions and is an invited speaker at seminars and regularly consults for private and public companies and elements of the Government. Michael has been a non-executive board member of Scythian Biosciences since inception and also acts as a non-executive board member and mentor to founders in early stage startups. Michael has a Bachelor's of Computer Science from London University, is a past Fellow of The Institute of Analysts & Programmers, member of the British Computer Society, Institute of Directors and is a Chartered Engineer.
Mr. Benz is a serial entrepreneur who has founded, invested and grown numerous companies in a cross-section of industry sectors. Mr. Benz has significant experience managing and directing both private and public companies and currently serves as Chairman of Optex Systems holdings Inc. (OTC), and as director and audit committee member of Cogint Inc. (Nasdaq), Lilis Energy Inc. (Nasdaq) and uSell.com Inc. (OTC). Mr. Benz is also currently involved with Viking Asset Management LLC a privately owned hedge fund sponsor investing in the public equity and alternative investment markets, where he has served as Chairman since 2002. Mr. Benz received his Bachelor of Business Administration (BBA) from the University of Notre Dame, USA in 1982.
Mr. Rai is the Managing Director of E. S. Rogers Enterprises and President of R3 Concepts Inc. As Managing Director at E.S. Rogers, Mr. Rai advises Edward Rogers on business, revenue, partnership and talent development. Mr. Rai was previously the Vice-President of Business Development of Peeks Social Ltd., a TSXV listed company operating Keeks.com, a social networking service focusing on video content. Mr. Rai has managed and directed both private the public companies, having been a director for Sustain Co. Inc. (SMS), Pintree Capital Ltd. (PNP) and The Mint Corporation. Mr. Rai has significant experienced in the digital and telecommunications markets, having held various managerial positions. Mr. Rai is the founder and a director of the ONEXONE foundation, a charitable organization focused on global child welfare. Born and raised in Toronto, Ontario, Mr. Rai received his Bachelor of Arts (BA) from the University of Western Ontario.
Board of Directors, numerous public companies
For contact sports players, repeated concussions can have devastating effects later in life. Chronic traumatic encephalopathy (CTE), a disease symptomatically similar to Alzheimer's, as well as other forms of dementia have been linked to repeated concussive episodes for which there is no FDA approved drug regimen. While it is difficult to prevent concussions entirely in contact sports, Scythian believes that through its unique technology, brain damage caused by concussions can be greatly mitigated by easing the aftereffects of the brain's contact with the skull.
To understand how, it is critical to understand how brain damage is caused once the brain hits the skill. The actual impact is not necessarily the most damaging part, but rather the body's natural response afterward that exacerbates brain injury.
Within the first few hours of a concussion, the inflammatory response is triggered, causing swelling of brain tissue. Just as any area of the body begins to swell after impact and injury due to inflammation, brain tissue itself does as well. Unfortunately, because the brain is confined inside the skull, the inflammation naturally triggered ends up causing even more damage as the process continually pushes already-injured brain tissue against bone.
While this is going on in the immediate aftermath of a concussion, the inflammatory response then leads way to an immune response with the corresponding infiltration of white blood cells and the release of immune modulators called cytokines. This itself further worsens brain injury as it continues to push against the brain.
Most of the damage then, occurs during the inflammatory and immune responses in the aftermath of injury. It is specifically these processes that Scythian's patent pending technology aims to control, thereby helping the body repair brain tissue without the associated swelling and white blood cell infiltration.
The way Scythian accomplishes this is through a combination of drug molecules called CB2 receptor agonists and NMDA receptor antagonists. CB2 receptor agonists, principally a compound known as cannabidiol (CBD), is a non-psychoactive cannabinoid compound naturally found in the marijuana plant that is known to resolve inflammation without the associated high, quickly, effectively, and systemically shutting the inflammatory response down. NMDA receptor antagonists on the other hand modulate the immune response, lessening and eventually eliminating white blood cell infiltration and cytokine release into brain tissue.
The effect is to, first, prevent the brain from swelling and being pushed against the skull, allowing it to heal without incurring additional damage following impact. Scythian believes that this unique drug combination, if applied immediately after a concussion, can help significantly lessen the long term impact of traumatic brain injury later in life.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.